Navigation Links
New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)
Date:5/14/2008

ore aggressive BP target of < 130/80 mm Hg (placebo: 6.9%). In addition, in another sub analysis, the study demonstrated that nearly seven out of ten (cumulative 69%) with stage 2 hypertension were able to reach the < 140/90 mm Hg blood pressure goal recommended by the JNC 7 (placebo: 16.9%). Stage 1 hypertension is defined by the JNC 7 as systolic blood pressure (SBP) of 140-159 mm Hg or diastolic blood pressure (DBP) of 90-99 mm Hg; Stage 2 hypertension is defined as 160/100 mm Hg or higher(1).

"These results are very encouraging as we in the cardiovascular community have been advocating to more aggressively fight hypertension," said Suzanne Oparil M.D., Director, Vascular Biology & Hypertension Program, University of Alabama at Birmingham, lead investigator of the study and President of ASH. "The study showed the ability of a regimen of BENICAR and BENICAR HCT to lower blood pressure beyond 140/90 mm Hg to the more aggressive normotensive target."

In the overall study, both stage 1 and stage 2 patients receiving BENICAR HCT 40/25 mg saw their seated systolic blood pressure (SeSBP) drop a mean of 23 mm Hg from a mean SBP baseline of 158 mm Hg (placebo: -2.6 mm Hg). In addition, more than one in four patients (27 percent) reached normotension, defined as < 120/80 mm Hg (placebo: 1.5%).

Of this study patient population, those with stage 2 hypertension achieved very good results with this regimen of BENICAR and BENICAR HCT. Of those titrated up to the maximum dose of 40/25mg, a cumulative 69 percent achieved a BP of < 140/90 mm Hg (placebo: 17%) while a cumulative 15 percent achieved a BP of < 120/80 mm Hg (placebo: 1.5%). For those with stage 2 hypertension, the average BP reduction for those patients on BENICAR 40/25 mg was 25/14 mm Hg (placebo: 6.2/1.9 mm Hg).

Hypertension, also known as high blood pressure, affects approximately 73 million people in the United States and approximately one billion worldwide(2,3). Called the "silent kill
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
2. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
3. St. Jude Study Shows How T Cells Machinery Dials Down Autoimmunity
4. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
5. NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting
6. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
7. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
8. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
9. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
10. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
11. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) ... Diagnostic Testing Market - Forecasts to 2019: Expected ... and is expected to be valued at USD ... http://photos.prnewswire.com/prnh/20130307/600769 ... segmented according to immunoprotein types which include immunoglobulins, ...
(Date:7/11/2014)... July 11, 2014 ... Safety & Health Expo 2014 were a ... to London , plus ... exhibition.          (Logo: ... )      (Photo: ...
(Date:7/10/2014)... July 11, 2014  Major advances in radiation ... are being highlighted in a three-day Oncology Summit ... from 10-12 July, 2014.  Renowned national and international cancer experts ... practices and exchange knowledge on modern technologies making ... efficient. The Summit will address ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... Aug. 17, 2011 Reportlinker.com announces that ... in its catalogue: Levosimendan ... http://www.reportlinker.com/p0483048/Levosimendan---Comprehensive-patent-search.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Eliminate unnecessary ... patent information. Pipeline Developer is ...
... 16, 2011 Savient Pharmaceuticals, Inc. (NASDAQ: ... KRYSTEXXA® (pegloticase) Phase III clinical studies in patients with ... The Journal of the American Medical Association ( ... resulted in significant and sustained reductions in uric acid ...
Cached Medicine Technology:Levosimendan - Comprehensive Patent Search 2Levosimendan - Comprehensive Patent Search 3Levosimendan - Comprehensive Patent Search 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 2Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 5Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 6Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 7Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 8
(Date:7/11/2014)... Williamsburg, VA (PRWEB) July 11, 2014 Riverside ... Continuing Care (CBCC) in Virginia in late 2012 and ... – ChooseHome – to residents throughout the Williamsburg and Newport ... CBCC programs provide services and benefits to independent older adults ... have access to a safety net of continuing care services ...
(Date:7/11/2014)... TX (PRWEB) July 11, 2014 Last ... their staff. Jim Siddons joins the agency as a ... graduated in 1994 with a Bachelor’s Degree in Business ... of industry experience and will manage everything from performance ... for trucking to the specialized needs for those in ...
(Date:7/11/2014)... Europe is one of the largest consumers ... irrigated land area. The agricultural sector is a significant ... 30.0% of the total water use. The scale and ... region, but far from negligible in most northern ones. ... 60.0% of the water use in most countries, while ...
(Date:7/11/2014)... The “Proteomics Market by Technology (Protein Microarray, ... Resonance, X-ray Crystallography) - Instruments, Reagents & Services ... the major market drivers, restraints, and opportunities in ... the World (RoW). , The proteomics market has ... mainly due to the increasing need of proteomic ...
(Date:7/11/2014)... Pigments are insoluble colorants, which usually ... namely protective coating, opacity, and coloring. These are water ... color to substances such as paper, paints, plastics, and ... upon application impart color to the substance. Some examples ... and hematite. , The coloring action of pigments is ...
Breaking Medicine News(10 mins):Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 2Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 4Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3
... HARRISBURG, Pa., Jan. 3 Consumers who,purchased or ... from,the Schumacher,s Inn in Austin, Potter County, should ... Botulism contamination, Health Secretary Dr. Calvin B.,Johnson said ... the restaurant should,immediately contact the Pennsylvania Department of ...
... (OTC,Bulletin Board: RXEI), a developer, manufacturer, and marketer ... a registration,statement covering the resale of 53,747,555 shares ... and Exchange Commission on January,2, 2008., This ... does not,represent a solicitation or offer to buy ...
... mind can affect the body,s health, researchers say , , THURSDAY, ... say they have prescribed a placebo to a patient during ... A majority of doctors in the study also said they ... accept a mind-body relationship that can affect health, the ...
... faster cancer growth and earlier death, agency says ... studies offer further evidence of the health risks posed ... U.S. officials announced Thursday. , The studies showed that ... the drugs as treatment for chemotherapy-induced anemia died sooner ...
... treated for hypothyroidism aren,t likely to drop pounds with ... the Journal of Pediatrics. The study is the first ... loss in pediatric patients., Parents of overweight children ... request thyroid tests, but, unfortunately, screening for hypothyroidism is ...
... with radiation, finding no raised risk to heart , , ... that a common but controversial treatment for prostate cancer ... of heart problems, as some specialists had feared. ... a combination of testosterone-lowering drugs and radiation therapy appeared ...
Cached Medicine News:Health News:Health Department Warns Consumers of Home-Canned Soup Linked to Potter County Restaurant 2Health News:RxElite Registration Statement Declared Effective by Securities and Exchange Commission 2Health News:Almost Half of Doctors Have Prescribed Placebos 2Health News:FDA Reports New Risks Posed by Anemia Drugs 2Health News:FDA Reports New Risks Posed by Anemia Drugs 3Health News:Thyroid treatment no 'quick fix' for weight loss in children 2Health News:Combo Therapy Cuts Prostate Cancer Death Rates 2Health News:Combo Therapy Cuts Prostate Cancer Death Rates 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: